{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ETNA","nct_id":"NCT06078384","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=etna-nct06078384. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ETNA","arms":[{"description":"Pembrolizumab will be administered at a fixed dose of 200 mg every 3 weeks (Q3W), with a total of 9 cycles and Paclitaxel 80 mg/m² weekly for 12 cycles","label":"Cohort 1-Pembrolizumab plus Paclitaxel","type":"EXPERIMENTAL"},{"description":"No treatment will be administered, patients will undergo standard surveillance every 6 months according to local practice.","label":"Cohort 2-Observation","type":"NO_INTERVENTION"}],"collaborators":["MSD France","SOLTI Breast Cancer Research Group","Gustave Roussy, Cancer Campus, Grand Paris","Vall Hebron Insitut Recerca"],"completion_date":{"date":"2032-01-01","type":"ESTIMATED"},"conditions":["Triple-negative Breast Cancer"],"enrollment":{"count":354,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab 25 mg/ml","otherNames":["keytruda"],"type":"DRUG"},{"name":"Paclitaxel injection","otherNames":["Taxol"],"type":"DRUG"}],"last_update":"2026-07-24","lead_sponsor":"UNICANCER","official_title":"Adjuvant Pembrolizumab and Chemotherapy or Surveillance in Early Triple Negative breAst Cancer With High Stromal Tumor-infiltrating Lymphocytes (TILs) Score","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2032-01-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Distant disease-free survival (DDFS)","timeFrame":"5 year"}],"references":[],"start_date":{"date":"2024-12-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC","url":"https://clinicaltrials.gov/study/NCT06078384"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/etna-nct06078384"}